Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences presents updated clinical data for its CB-011 therapy, showing deep and durable responses in multiple myeloma patients. Social media buzz highlights positive trial results and investor interest despite broader biotech investment concerns.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. is a biotechnology company specializing in gene-edited cell therapies for cancer treatment.
Caribou Biosciences, Inc. uses the ticker $CRBU for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Caribou Biosciences, Inc. (CRBU) social dominance hit [------] which is 246% higher than it's daily average.
- Caribou Biosciences, Inc. (CRBU) social dominance is up 655.17% from the previous [--] months.
- Caribou Biosciences, Inc. (CRBU) mentions is up 3728.57% from the previous month.
- Caribou Biosciences, Inc. (CRBU) posts created is up 88.89% from the previous week.
Price: $1.60
Price 24-Hour Time-Series Raw Data
Despite a recent price decline, a surge in social engagements and mentions, coupled with positive analyst ratings and upcoming data presentations, suggests growing investor interest that could influence future stock performance.
24-Hour: 3.95% 7-Day: 1.28% 30-Day: 8.22%
1-Year High: $2.80 on 2025-10-15
1-Year Low: $1.10 on 2025-06-05
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
Caribou Biosciences, Inc. (CRBU) is currently AltRank #1,024 based on combined combined social and market metrics
Daily Average: [-----]
[--] Week: [-----] [----]
1-Year High: [-----] on 2026-02-11
1-Year Low: [---] on 2026-01-24
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] +15
[--] Months: [--] [---]
[--] Year: [--] +17
1-Year High: [--] on 2026-01-23
1-Year Low: [--] on 2025-06-05
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [------] -22%
[--] Month: [-------] +94%
[--] Months: [-------] -8.10%
[--] Year: [---------] -29%
1-Year High: [-------] on 2025-11-03
1-Year Low: [---] on 2025-10-12
Engagements by network (24h): News: [--] Reddit: [--] TikTok: [--] X: [-----] YouTube: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [---] +42%
[--] Month: [---] +3,729%
1-Year High: [---] on 2025-11-04
1-Year Low: [--] on 2025-10-13
Mentions by network (24h): News: [--] Reddit: [--] TikTok: [--] X: [--] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Caribou Biosciences, Inc. (CRBU) in the last [--] hours which is down 56% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [---] +8%
[--] Month: [---] +1,407%
1-Year High: [---] on 2025-11-04
1-Year Low: [--] on 2025-10-13
The most influential creators that mention Caribou Biosciences, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @yaireinhorn | [--] | [------] | [--] | [---] |
| @Lola59652 | [--] | [--] | [--] | [---] |
| @Trade_market9 | [--] | [---] | [--] | [--] |
| @Stock_Analysis6 | [--] | [---] | [--] | [--] |
| @Angelinafrazier | [--] | [--] | [--] | |
| @BuyTheUgly | [--] | [--] | [--] | [--] |
| @Stock_Marketr15 | [--] | [---] | [--] | [--] |
| @RazorSharpDNA | [--] | [-----] | [--] | [--] |
| @stocket_rocket | [--] | [--] | [--] | [--] |
| @hg19290 | [--] | [--] | [--] | [--] |
Sentiment: 58%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 58%
Daily Average: 75%
[--] Week: 17% -26%
[--] Month: 50% -15%
[--] Months: 50% -38%
[--] Year: 50% -39%
1-Year High: 100% on 2025-02-18
1-Year Low: 17% on 2026-01-10
Most Supportive Themes:
- Gene Editing for Cancer Therapy: (50%) Caribou Biosciences is a biotechnology company focused on developing gene-edited cell therapies to treat cancer.
- CRISPR Technology Advancement: (30%) The company utilizes CRISPR technology, a powerful tool for gene editing, in its therapeutic development.
Most Critical Themes:
- US Biotech Investment Concerns: (70%) There is a sentiment that Wall Street is not adequately supporting US-based gene editing companies, potentially posing a national security risk.
Social Dominance: 0.00718%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00718%
Daily Average: 0.00633%
[--] Week: 0.00917% +0.00127%
[--] Month: 0.022% +0.017%
[--] Months: 0.022% +0.019%
[--] Year: 0.022% +0.016%
1-Year High: 0.072% on 2025-11-04
1-Year Low: 0.0006% on 2025-10-13
Market Dominance: 0.00016728722383926113%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00016728722383926113%
Daily Average: 0%
1-Year High: 0.00678% on 2026-02-06
1-Year Low: 0.00017% on 2026-02-16
Market Cap: $147,679,500
Market Cap 24-Hour Time-Series Raw Data
Current Value: $147,679,500
Daily Average: $142,765,752
[--] Week: $147,679,500 -2.80%
[--] Month: $147,679,500 +8.20%
1-Year High: $152,352,902 on 2026-02-09
1-Year Low: $129,920,573 on 2026-01-20
Top Caribou Biosciences, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"crispr isnt dead but $EDIT is. Hard to understand what MIT is thinking here. They keep cannibalizing their wins. Not sure yet if the same fate awaits $PRME and $CRBU. Someone needs to write a lesson book on how these people squandered a once-in a lifetime opportunity"
X Link @marketfrankford 2026-02-14T17:43Z [---] followers, [---] engagements
"Very well done $CRBU and strong data imo @CaribouBio 👏 Thanks for the great write up @yaireinhorn Likey will re-enter here in coming months. Pure cell therapy plays I like for [----] include CRBU $IPSC $FATE 1/🚨WOW $CRBU has presented updated clinical data from @CaribouBio ongoing CB-011 CaMMouflage phase [--] clinical trial in cancer patients with relapsed or refractory multiple myeloma (r/r MM). The CB-011 CaMMouflage phase [--] translational and clinical data - which was presented at https://t.co/emfrwEHgux 1/🚨WOW $CRBU has presented updated clinical data from @CaribouBio ongoing CB-011"
X Link @BiomedicalRX 2026-02-09T16:30Z [----] followers, [----] engagements
"1/🚨WOW $CRBU has presented updated clinical data from @CaribouBio ongoing CB-011 CaMMouflage phase [--] clinical trial in cancer patients with relapsed or refractory multiple myeloma (r/r MM). The CB-011 CaMMouflage phase [--] translational and clinical data - which was presented at the [----] Tandem Meetings of ASTCT and CIBMTR demonstrated deep and durable responses and further support the potential of CB-011 as the best-in-class allogeneic CAR-T Cell Therapy for second-line relapsed or refractory multiple myeloma patients. $XBI 🧵👇 https://twitter.com/i/web/status/2020850523788673400"
X Link @yaireinhorn 2026-02-09T13:21Z 18.5K followers, 12.9K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing